Phaseline

Companies › Relay Therapeutics

Relay Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 2 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Other; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Zovegalisib (RLY-2608)
PIK3CA inhibitor
PIK3CAPhase 3PIK3CA Mutation; PIK3CA-Related Overgrowth Spectrum (PROS)Apr 2027
RLY-8161
NRAS-selective inhibitor
NRASPhase 1Advanced NRAS-Mutant MelanomaMay 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05216432Zovegalisib (RLY-2608)Phase 1PIK3CA MutationOncologyApr 2027
NCT06982521Zovegalisib (RLY-2608)Phase 3PIK3CA MutationOncologyApr 2028
NCT07584226RLY-8161Phase 1Advanced NRAS-Mutant MelanomaOncologyMay 2029
NCT06789913Zovegalisib (RLY-2608)Phase 2PIK3CA-Related Overgrowth Spectrum (PROS)OtherJul 2031

From the company's SEC filings

Cash of $124m on 2026-09-30; operating cash outflow about $227m a year; runway about 7 months at that burn, to Apr 2027; 0 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

NRAS (1) PIK3CA (1)

Companies with the same targets

Eli Lilly TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Adlai Nortye Biopharma Guangzhou JOYO Pharma Elicio Therapeutics Shanghai YingLi Pharmaceutical Novartis Recursion Pharmaceuticals Totus Medicines Risen (Suzhou) Pharma Tech

Companies built like this

Aura Biosciences Haihe Biopharma Immuneering Tyra Biosciences UroGen Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.